Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.

Guix M, Granja Nde M, Meszoely I, Adkins TB, Wieman BM, Frierson KE, Sanchez V, Sanders ME, Grau AM, Mayer IA, Pestano G, Shyr Y, Muthuswamy S, Calvo B, Krontiras H, Krop IE, Kelley MC, Arteaga CL
J Clin Oncol. 2008 26 (6): 897-906

PMID: 18180460 · DOI:10.1200/JCO.2007.13.5939

MeSH Terms (31)

Adult Aged Animals Antineoplastic Agents Biomarkers, Tumor Breast Neoplasms Cell Proliferation Chemotherapy, Adjuvant ErbB Receptors Erlotinib Hydrochloride Female Humans Immunohistochemistry In Situ Nick-End Labeling Ki-67 Antigen Mice Mice, Nude Middle Aged Neoadjuvant Therapy Neoplasms, Hormone-Dependent Neoplasm Staging Protein-Tyrosine Kinases Protein Kinase Inhibitors Quinazolines Receptor, ErbB-2 Receptors, Estrogen Receptors, Progesterone Signal Transduction Tandem Mass Spectrometry Treatment Outcome Xenograft Model Antitumor Assays

Connections (5)

This publication is referenced by other Labnodes entities:

Links